CR20140264A - Combinación terapéutica de memantina y baclofeno y composición farmacéutica que los contiene - Google Patents
Combinación terapéutica de memantina y baclofeno y composición farmacéutica que los contieneInfo
- Publication number
- CR20140264A CR20140264A CR20140264A CR20140264A CR20140264A CR 20140264 A CR20140264 A CR 20140264A CR 20140264 A CR20140264 A CR 20140264A CR 20140264 A CR20140264 A CR 20140264A CR 20140264 A CR20140264 A CR 20140264A
- Authority
- CR
- Costa Rica
- Prior art keywords
- baclofen
- memantine
- pharmaceutical composition
- composition containing
- therapeutic combination
- Prior art date
Links
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 title abstract 2
- 229960000794 baclofen Drugs 0.000 title abstract 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 title abstract 2
- 229960004640 memantine Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a la combinación de memantina y al ingrediente activo de baclofeno, y también al método para lograr la pérdida de peso corporal y por lo tanto el tratamiento de la obesidad y co-morbilidades relacionadas mediante la co-ad
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1100615A HU230263B1 (hu) | 2011-11-07 | 2011-11-07 | Memantin és baclofen hatóanyagokat tartalmazó kombinációs készítmény |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20140264A true CR20140264A (es) | 2014-07-11 |
Family
ID=89990495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20140264A CR20140264A (es) | 2011-11-07 | 2014-06-04 | Combinación terapéutica de memantina y baclofeno y composición farmacéutica que los contiene |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20140316007A1 (es) |
| EP (1) | EP2776019A1 (es) |
| JP (1) | JP2014532752A (es) |
| KR (1) | KR20140090203A (es) |
| CN (1) | CN103930099A (es) |
| AU (1) | AU2012335358A1 (es) |
| BR (1) | BR112014010892A2 (es) |
| CA (1) | CA2853872A1 (es) |
| CL (1) | CL2014001167A1 (es) |
| CO (1) | CO6970599A2 (es) |
| CR (1) | CR20140264A (es) |
| CU (1) | CU20140052A7 (es) |
| EA (1) | EA201490935A1 (es) |
| HK (1) | HK1200101A1 (es) |
| HU (1) | HU230263B1 (es) |
| IL (1) | IL232232A0 (es) |
| IN (1) | IN2014KN01142A (es) |
| MX (1) | MX2014005499A (es) |
| NI (1) | NI201400039A (es) |
| PE (1) | PE20141576A1 (es) |
| SG (1) | SG11201401693UA (es) |
| WO (1) | WO2013068774A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040102525A1 (en) * | 2002-05-22 | 2004-05-27 | Kozachuk Walter E. | Compositions and methods of treating neurological disease and providing neuroprotection |
| CN101500610A (zh) * | 2006-08-11 | 2009-08-05 | 国立大学法人名古屋大学 | 抗肥胖药及其利用 |
| EP2058008B1 (en) * | 2006-08-11 | 2013-08-21 | National University Corporation Nagoya University | Anti-obesity agent and use thereof |
-
2011
- 2011-11-07 HU HU1100615A patent/HU230263B1/hu unknown
-
2012
- 2012-11-06 SG SG11201401693UA patent/SG11201401693UA/en unknown
- 2012-11-06 MX MX2014005499A patent/MX2014005499A/es unknown
- 2012-11-06 PE PE2014000619A patent/PE20141576A1/es not_active Application Discontinuation
- 2012-11-06 EP EP12795610.0A patent/EP2776019A1/en not_active Withdrawn
- 2012-11-06 BR BR112014010892A patent/BR112014010892A2/pt not_active Application Discontinuation
- 2012-11-06 JP JP2014540561A patent/JP2014532752A/ja active Pending
- 2012-11-06 IN IN1142KON2014 patent/IN2014KN01142A/en unknown
- 2012-11-06 EA EA201490935A patent/EA201490935A1/ru unknown
- 2012-11-06 CN CN201280054371.7A patent/CN103930099A/zh active Pending
- 2012-11-06 US US14/356,096 patent/US20140316007A1/en not_active Abandoned
- 2012-11-06 WO PCT/HU2012/000119 patent/WO2013068774A1/en active Application Filing
- 2012-11-06 CA CA2853872A patent/CA2853872A1/en not_active Abandoned
- 2012-11-06 AU AU2012335358A patent/AU2012335358A1/en not_active Abandoned
- 2012-11-06 KR KR1020147012752A patent/KR20140090203A/ko not_active Application Discontinuation
-
2014
- 2014-04-24 IL IL232232A patent/IL232232A0/en unknown
- 2014-04-29 CU CU2014000052A patent/CU20140052A7/es unknown
- 2014-05-05 NI NI201400039A patent/NI201400039A/es unknown
- 2014-05-05 CL CL2014001167A patent/CL2014001167A1/es unknown
- 2014-05-29 CO CO14116553A patent/CO6970599A2/es unknown
- 2014-06-04 CR CR20140264A patent/CR20140264A/es unknown
-
2015
- 2015-01-16 HK HK15100547.1A patent/HK1200101A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2853872A1 (en) | 2013-05-16 |
| HK1200101A1 (en) | 2015-07-31 |
| HUP1100615A2 (en) | 2013-06-28 |
| JP2014532752A (ja) | 2014-12-08 |
| NI201400039A (es) | 2014-10-02 |
| IL232232A0 (en) | 2014-06-30 |
| CN103930099A (zh) | 2014-07-16 |
| CL2014001167A1 (es) | 2014-07-04 |
| IN2014KN01142A (es) | 2015-10-16 |
| SG11201401693UA (en) | 2014-05-29 |
| BR112014010892A2 (pt) | 2017-06-13 |
| CO6970599A2 (es) | 2014-06-13 |
| WO2013068774A1 (en) | 2013-05-16 |
| AU2012335358A1 (en) | 2014-05-29 |
| CU20140052A7 (es) | 2014-07-30 |
| PE20141576A1 (es) | 2014-11-06 |
| EA201490935A1 (ru) | 2014-08-29 |
| EP2776019A1 (en) | 2014-09-17 |
| KR20140090203A (ko) | 2014-07-16 |
| HU230263B1 (hu) | 2015-11-30 |
| US20140316007A1 (en) | 2014-10-23 |
| MX2014005499A (es) | 2015-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP18048718A (es) | Imidazolilimidazoles condensados como compuestos antivirales | |
| CO2017013708A2 (es) | Macrociclos peptídicos contra acinetobacter baumannii. | |
| NI201400032A (es) | Piridopirazinas anticancerígenas via la | |
| ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
| PE20151067A1 (es) | Inhibidores de autotaxina | |
| PE20151178A1 (es) | Analogos de glucagon | |
| CR20160518A (es) | Compuestos para tratar atrofia muscular espinal | |
| GT201500030A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| DOP2014000115A (es) | Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| ECSP11011517A (es) | Compuestos antivirales | |
| CO6821938A2 (es) | Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1 | |
| GT201300174A (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme) | |
| ECSP13013021A (es) | Compuestos de benzotiazol y su uso farmacéutico | |
| UY34859A (es) | Análogos peptídicos de la exendina 4. | |
| GT201200334A (es) | Morfolinopirimidinas y su uso en terapia | |
| EA201590053A1 (ru) | Модуляторы пути системы комплемента и их применение | |
| GT201200004A (es) | Imidazoles fusionados y composiciones que los contienen para el tratamiento de enfermedades parasitarias, como por ejemplo malaria | |
| CR20130530A (es) | Derivados glucósidos y sus usos para el tratamiento de la diabetes | |
| MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
| DOP2015000070A (es) | Procedimientos para fabricar medicamentos útiles para tratar artritis reumatoide | |
| ES2429422R1 (es) | Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH | |
| GT201400161A (es) | Fenilimidazopirazoles sustituidos y su uso | |
| UY33348A (es) | Compuestos de furopiridina y usos de los mismos | |
| CL2010001577A1 (es) | Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias. | |
| CO7121334A2 (es) | Formulaciones vesiculares |